We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

93 hedge funds and large institutions have $627M invested in Coherus Oncology in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 44 increasing their positions, 24 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 24

13.09% more ownership

Funds ownership: 78.28% → 91.37% (+13%)

9% more capital invested

Capital invested by funds: $576M → $627M (+$50.5M)

12% less funds holding

Funds holding: 106 → 93 (-13)

26% less call options, than puts

Call options by funds: $1.43M | Put options by funds: $1.92M

57% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 21

Holders
93
Holders Change
-13
Holders Change %
-12.26%
% of All Funds
2.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
44
Reduced
24
Closed
21
Calls
$1.43M
Puts
$1.92M
Net Calls
-$491K
Net Calls Change
-$3.57M

Top Buyers

Rank Fund Capital Flow
1
Temasek Holdings
Temasek Holdings
Singapore
+$86.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$18.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.98M
4
State Street
State Street
Massachusetts
+$6.08M
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.76M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$25.9M
2
CAM
Cormorant Asset Management
Massachusetts
-$8.9M
3
CC
Carlson Capital
Texas
-$3.84M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$3.24M
5
CCI
Columbus Circle Investors
-$2.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$2.58M – – –
Citadel Advisors
27
Citadel Advisors
Florida
$2.57M -$535K -40,407 -17%
USAA
28
United Services Automobile Association
Texas
$2.45M +$324K +24,515 +15%
RPAM
29
Rhenman & Partners Asset Management
Sweden
$2.4M +$147K +11,128 +7%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.32M +$49K +3,701 +2%
Charles Schwab
31
Charles Schwab
California
$2.11M -$48.7K -3,685 -2%
Wells Fargo
32
Wells Fargo
California
$2.06M +$1.65M +124,910 +429%
Goldman Sachs
33
Goldman Sachs
New York
$1.96M +$75.1K +5,674 +4%
EAM
34
Eventide Asset Management
Massachusetts
$1.94M – – –
CS
35
Credit Suisse
Switzerland
$1.9M -$96.2K -7,270 -5%
PIM
36
Platinum Investment Management
Australia
$1.46M +$1.44M +109,200 New
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$1.43M -$162K -12,279 -10%
KCM
38
Kennedy Capital Management
Missouri
$1.31M -$25.6K -1,938 -2%
TCM
39
Tekla Capital Management
Massachusetts
$1.2M – – –
TA
40
Teachers Advisors
New York
$1.13M +$3.49K +264 +0.3%
Deutsche Bank
41
Deutsche Bank
Germany
$1.07M -$19.1K -1,447 -2%
Millennium Management
42
Millennium Management
New York
$962K +$565K +42,693 +145%
Handelsbanken Fonder
43
Handelsbanken Fonder
Sweden
$934K +$198K +15,000 +27%
PAMU
44
Pictet Asset Management (UK)
United Kingdom
$843K +$502K +37,942 +151%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$835K -$71.3K -5,387 -8%
Thrivent Financial for Lutherans
46
Thrivent Financial for Lutherans
Minnesota
$762K – – –
Morgan Stanley
47
Morgan Stanley
New York
$756K -$56.5K -4,268 -7%
Swiss National Bank
48
Swiss National Bank
Switzerland
$697K – – –
NFA
49
Nationwide Fund Advisors
Ohio
$637K – – –
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$582K – – –
1
2
3 4 5

CHRS Hedge Fund Activity: Q3 2017 in Review

93 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2017, worth a combined $627M — up 8.8% from $576M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CHRS and 9 opened new positions — a net loss of 12 holders — while 24 trimmed existing stakes and 44 added.

The largest buyer was Temasek Holdings, opening a new position worth an estimated $86.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.9M sold.

  • 93 institutional investors held Coherus Oncology (CHRS) as of Q3 2017, down from 106 in Q2 2017.
  • Funds reported $627M of Coherus Oncology stock for Q3 2017, up 8.8% quarter-over-quarter.
  • 9 funds opened new Coherus Oncology positions in Q3 2017 and 21 closed out, a net change of -12 holders.
  • The largest Coherus Oncology buyer in Q3 2017 was Temasek Holdings, an estimated $86.7M added.
  • The largest Coherus Oncology seller in Q3 2017 was PFM Health Sciences, an estimated $25.9M sold.

Based on aggregated 13F filings for Q3 2017.